Neurotech International Intensifies NTI164 Development with Strong Clinical Data, New Leadership, and Strategic Manufacturing Partnership
Neurotech International (ASX: NTI) is marking a significant period of advancement in its mission to develop NTI164, a proprietary broad-spectrum oral cannabinoid therapy, for rare paediatric neurological disorders. The company has unveiled a series of critical achievements, including robust clinical data, strategic leadership appointments, and key manufacturing agreements, positioning NTI164 for accelerated development and potential…

